Literature DB >> 23273695

Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation.

Richard Chang1, John A Butman, Russell R Lonser, Richard M Sherry, Prakash K Pandalai, McDonald K Horne, Jay N Lozier.   

Abstract

Seven patients with venous thrombosis and contraindications to traditional thrombolytic therapy, consisting of recent intracranial surgery, recent pineal or retroperitoneal hemorrhage, active genitourinary or gastrointestinal bleeding, epidural procedures, and impending surgery, were successfully treated with a modified thrombolytic regimen. To improve safety, prolonged continuous infusions of tissue plasminogen activator (tPA) was eliminated in favor of once-daily low-dose intraclot injections of tPA to minimize the amount and duration of tPA in the systemic circulation, and low-therapeutic or regional anticoagulation was used to reduce anticoagulant risks. These modifications may allow thrombolytic treatment for selected patients with severe venous thrombosis who are deemed to be at high risk.
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23273695      PMCID: PMC3636547          DOI: 10.1016/j.jvir.2012.09.017

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  14 in total

1.  Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal.

Authors:  Suresh Vedantham; Patricia E Thorpe; John F Cardella; Clement J Grassi; Nilesh H Patel; Hector Ferral; Lawrence V Hofmann; Bertrand M Janne d'Othée; Vittorio P Antonaci; Elias N Brountzos; Daniel B Brown; Louis G Martin; Alan H Matsumoto; Steven G Meranze; Donald L Miller; Steven F Millward; Robert J Min; Calvin D Neithamer; Dheeraj K Rajan; Kenneth S Rholl; Marc S Schwartzberg; Timothy L Swan; Richard B Towbin; Bret N Wiechmann; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2006-03       Impact factor: 3.464

2.  Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.

Authors:  K Ouriel; B Gray; D G Clair; J Olin
Journal:  J Vasc Interv Radiol       Date:  2000-03       Impact factor: 3.464

3.  Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis.

Authors:  Richard Chang; McDonald K Horne; Thomas H Shawker; Anthony W Kam; Enn Alexandria Chen; Galen O Joe; Willie L Ching; Edie Mao; David A Wyrick; Jay N Lozier
Journal:  J Vasc Interv Radiol       Date:  2011-06-12       Impact factor: 3.464

Review 4.  Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism.

Authors:  M N Levine; S Z Goldhaber; J M Gore; J Hirsh; R M Califf
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

5.  Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity.

Authors:  R Chang; R O Cannon; C C Chen; J L Doppman; T H Shawker; D J Mayo; B Wood; M K Horne
Journal:  J Vasc Interv Radiol       Date:  2001-02       Impact factor: 3.464

6.  Biochemical dynamics relevant to the safety of low-dose, intraclot alteplase for deep vein thrombosis.

Authors:  Jay N Lozier; Ann M Cullinane; Khanh Nghiem; Richard Chang; McDonald K Horne
Journal:  Transl Res       Date:  2012-02-23       Impact factor: 7.012

7.  Catheter-directed thrombolysis for acute limb ischemia.

Authors:  Harry L Morrison
Journal:  Semin Intervent Radiol       Date:  2006-09       Impact factor: 1.513

8.  Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).

Authors:  Terese T Horlocker; Denise J Wedel; John C Rowlingson; F Kayser Enneking; Sandra L Kopp; Honorio T Benzon; David L Brown; John A Heit; Michael F Mulroy; Richard W Rosenquist; Michael Tryba; Chun-Su Yuan
Journal:  Reg Anesth Pain Med       Date:  2010 Jan-Feb       Impact factor: 6.288

9.  A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

Authors:  M N Levine; J Hirsh; M Gent; A G Turpie; M Cruickshank; J Weitz; D Anderson; M Johnson
Journal:  Arch Intern Med       Date:  1994-01-10

10.  Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.

Authors:  Michael R Grunwald; Lawrence V Hofmann
Journal:  J Vasc Interv Radiol       Date:  2004-04       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.